Skip to content
Does Operation Warp Speed Deserve Credit for Pfizer’s Success in Developing a COVID Vaccine?
Khaya Himmelman /

Does Operation Warp Speed Deserve Credit for Pfizer’s Success in Developing a COVID Vaccine?

The pharma giant did not take federal money for research and development, but it did sign an advance purchase agreement.
Does Operation Warp Speed Deserve Credit for Pfizer’s Success in Developing a COVID Vaccine?

On Monday, Pfizer announced that in trials, its COVID-19 vaccine candidate was more than 90 percent effective in preventing the disease. Pfizer, which is developing the vaccine in conjunction with German drug company BioNTech, is now, according to a press release from the company: “working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.”

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Khaya Himmelman is a fact checker for The Dispatch. She is a graduate of Columbia Journalism School and Barnard College.

More We Think You’d Like

Loading